1 NAME OF THE MEDICINE
Fosaprepitant dimeglumine

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial of EMEND IV 150 mg for intravenous administration contains 245.3 mg of fosaprepitant dimeglumine equivalent to 150 mg fosaprepitant free acid.

List of excipients with known effect:
- lactose monohydrate

For the full list of Excipients, see Section 6.1 List of Excipients.

3 PHARMACEUTICAL FORM
EMEND IV (fosaprepitant dimeglumine) is a white to off white solid powder for injection.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS
EMEND IV, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:

- highly emetogenic cancer chemotherapy (see Section 4.2 Dose and Method of Administration)
- moderately emetogenic cancer chemotherapy (see Section 4.2 Dose and Method of Administration).

4.2 DOSE AND METHOD OF ADMINISTRATION

Dosage recommendations
EMEND IV, for administration by intravenous infusion, is a lyophilised prodrug of aprepitant containing polysorbate 80 (PS80).

EMEND IV 150 mg
EMEND IV 150 mg is administered on Day 1 as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. EMEND IV should be administered in conjunction with a corticosteroid and a 5-HT3 antagonist as specified in the tables below. The package insert for the co-administered 5-HT3 antagonist must be consulted prior to initiation of treatment with EMEND IV 150 mg.
Table 1: Recommended dosing for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy

<table>
<thead>
<tr>
<th></th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMEND IV</td>
<td>150 mg IV</td>
<td>none</td>
<td>none</td>
<td>none</td>
</tr>
<tr>
<td>Dexamethasone**</td>
<td>12 mg orally</td>
<td>8 mg orally</td>
<td>8 mg orally bid</td>
<td>8 mg orally bid</td>
</tr>
<tr>
<td>5-HT₃ antagonist</td>
<td>See the package insert for the selected 5-HT₃ antagonist for appropriate dosing information.</td>
<td>none</td>
<td>none</td>
<td>none</td>
</tr>
</tbody>
</table>

** Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 through 4. Dexamethasone should also be administered in the evenings on Days 3 and 4. The dose of dexamethasone accounts for drug interactions.

Table 2: Recommended dosing for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy

<table>
<thead>
<tr>
<th></th>
<th>Day 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMEND IV</td>
<td>150 mg IV</td>
</tr>
<tr>
<td>Dexamethasone**</td>
<td>12 mg orally</td>
</tr>
<tr>
<td>5-HT₃ antagonist</td>
<td>See the package insert for the selected 5-HT₃ antagonist for appropriate dosing information.</td>
</tr>
</tbody>
</table>

** Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1. The dose of dexamethasone accounts for drug interactions.

Preparation of EMEND IV for Injection 150 mg
1. Inject 5 mL saline into the vial. Assure that saline is added to the vial along the vial wall in order to prevent foaming. Swirl the vial gently. Avoid shaking and jetting saline into the vial.
2. Prepare an infusion bag filled with 145 mL of saline.
3. Withdraw the entire volume from the vial and transfer it into an infusion bag containing 145 mL of saline to yield a total volume of 150 mL. Gently invert the bag 2-3 times.*
4. To avoid microbiological hazard, the EMEND IV solution should be used as soon as practicable after reconstitution and further dilution. If storage is unavoidable, the solution should be held at 2-8°C for not more than 24 hours.
5. Parenteral drug products should be inspected visually for particulate matter and discolouration before administration whenever solution and container permit.
6. EMEND IV 150 mg should only be administered as an infusion over 20-30 minutes.

Product is for single use in one patient only. Discard any residue.

* Please Note: there is a 5% overage in each vial to account for non-withdrawable losses and to ensure that the labelled dose of 150 mg is deliverable after reconstitution.

GENERAL INFORMATION
See Section 4.5 Interactions with Other Medicines and Other Forms of Interactions for additional information on the administration of EMEND IV with corticosteroids.
Refer to the full prescribing information for coadministered antiemetic agents.

No dosage adjustment is necessary based on age, gender, race, or Body Mass Index.

No dosage adjustment is necessary for patients with severe renal insufficiency (creatinine clearance <30 mL/min) or for patients with end stage renal disease undergoing haemodialysis.
No dosage adjustment is necessary for patients with mild to moderate hepatic insufficiency (Child-Pugh score 5 to 9). There are no clinical data in patients with severe hepatic insufficiency (Child-Pugh score >9).

4.3 CONTRAINDICATIONS

EMEND IV is contraindicated in patients who are hypersensitive to EMEND IV, aprepitant, polysorbate 80 or any other components of the product.

EMEND IV should not be used concurrently with pimozide, terfenadine, astemizole, or cisapride. Inhibition of cytochrome P450 isoenzyme 3A4 (CYP3A4) by aprepitant could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Since fosaprepitant is rapidly converted to aprepitant, which is a dose dependent inhibitor of CYP3A4, fosaprepitant should be used with caution in patients receiving concomitant orally administered medicinal products that are primarily metabolized through CYP3A4; some chemotherapy agents are metabolized by CYP3A4 (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions). Weak inhibition of CYP3A4 by fosaprepitant 150 mg could result in elevated plasma concentrations of these concomitant medicinal products (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).

Immediate hypersensitivity reactions including flushing, erythema, rash, chest tightness, wheezing, dyspnea and anaphylaxis/anaphylactic shock have occurred during or soon after infusion of fosaprepitant. These hypersensitivity reactions have generally responded to discontinuation of the infusion and administration of appropriate therapy. It is not recommended to reinstitute the infusion in patients who experience hypersensitivity reactions.

Infusion site reactions (ISRs) have been reported with the use of EMEND IV (see Section 4.8 Adverse Effects (Undesirable Effects)). The majority of severe ISRs, including thrombophlebitis and vasculitis, were reported with concomitant vesicant (e.g., anthracycline-based) chemotherapy administration, particularly when associated with extravasation. Necrosis was also reported in some patients with concomitant vesicant chemotherapy.

Coadministration of fosaprepitant with warfarin may result in a clinically significant decrease in International Normalized Ratio (INR) of prothrombin time. In patients on chronic warfarin therapy, the INR should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of fosaprepitant with each chemotherapy cycle (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).

The efficacy of hormonal contraceptives during and for 28 days after administration of fosaprepitant may be reduced. Alternative or back-up methods of contraception should be used during treatment with fosaprepitant and for 1 month following administration of fosaprepitant (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).

Fosaprepitant should not be given as a bolus injection, but should always be diluted and given as a slow intravenous infusion (see Section 4.2 Dose and Method of Administration). Fosaprepitant should not be administered intramuscularly or subcutaneously. Mild injection site thrombosis has been observed at higher doses (see Section 4.9 Overdosage). If signs or symptoms of local irritation occur, the injection or infusion should be terminated and restarted in another vein.
Use in the elderly
See Section 5.2 Pharmacokinetic Properties, Elderly.

Paediatric use
See Section 5.2 Pharmacokinetic Properties, Paediatric patients.

Effects on laboratory tests
See Section 4.4 Special Warnings and Precautions for Use, INR monitoring as mentioned above, and Section 4.5 Interactions with other medicines and other forms of interactions, Warfarin.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

When administered intravenously, fosaprepitant is rapidly converted to aprepitant. Therefore, drug interactions following administration of fosaprepitant are likely to occur with drugs that interact with oral aprepitant. The following information was derived from studies conducted with oral aprepitant and studies conducted with fosaprepitant coadministered with dexamethasone, midazolam or diltiazem.

Aprepitant is a substrate, a weak to moderate inhibitor, and an inducer of CYP3A4. Aprepitant is also a moderate inducer of CYP2C9.

EMEND IV 150 mg, given as a single dose, is a weak inhibitor of CYP3A4, and does not induce CYP3A4. It is anticipated that EMEND IV 150 mg would cause less or no greater induction of CYP2C9 than that caused by the administration of oral aprepitant.

**Effect of fosaprepitant/aprepitant on the pharmacokinetics of other agents**

Aprepitant, as a weak to moderate inhibitor of CYP3A4, and EMEND IV 150 mg, as a weak inhibitor of CYP3A4, can increase plasma concentrations of orally coadministered medicinal products that are metabolised through CYP3A4.

Fosaprepitant should not be used concurrently with pimozide, terfenadine, astemizole, or cisapride. Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions (see Section 4.3 Contraindications). Caution should be exercised in using aprepitant concurrently with drugs which have a narrow therapeutic index and are known to be metabolised primarily by CYP3A4, such as ciclosporin, sirolimus and tacrolimus.

Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9. Coadministration of fosaprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.

Fosaprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of oral aprepitant with digoxin in a clinical drug interaction study.
5-HT3 antagonists:
In clinical drug interaction studies, aprepitant when given as a regimen of 125 mg on Day 1 and 80 mg on Days 2 and 3, did not have clinically important effects on the pharmacokinetics of ondansetron, granisetron, or hydrodolasetron (the active metabolite of dolasetron).

Corticosteroids:
Dexamethasone: Fosaprepitant 150 mg administered as a single intravenous dose on Day 1 increased the AUC0-24hr of dexamethasone, a CYP3A4 substrate, by approximately 2.0-fold on Days 1 and 2 when dexamethasone was coadministered as a single 8 mg oral dose on Days 1, 2, and 3. The oral dexamethasone dose on Days 1 and 2 should be reduced by approximately 50% when coadministered with fosaprepitant 150 mg IV on Day 1 to achieve exposures of dexamethasone similar to those obtained when given without fosaprepitant 150 mg (see Section 4.2 Dose and Method of Administration).

Methylprednisolone: Oral aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.3-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.

Chemotherapeutic agents:
Chemotherapy agents that are known to be metabolised by the CYP3A4 include docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine, vinblastine and vincristine. In clinical studies, oral aprepitant (125 mg/80 mg regimen) was administered commonly with etoposide, vinorelbine, and paclitaxel. The doses of these agents were not adjusted to account for potential drug interactions. Adequate data are not available on interactions between aprepitant and other chemotherapy agents primarily metabolised by CYP3A4. Particular caution and careful monitoring are advised in patients receiving these agents or other chemotherapy agents metabolised primarily by CYP3A4. Post-marketing events of neurotoxicity, a potential adverse reaction of ifosfamide, have been reported after aprepitant and ifosfamide coadministration (see Section 4.4 Special Warnings and Precautions for Use).

Docetaxel: In an interaction study, oral aprepitant (CINV regimen) did not influence the pharmacokinetics of docetaxel.

Vinorelbine: In a separate pharmacokinetic study, oral aprepitant (CINV regimen) did not influence the pharmacokinetics of vinorelbine.

Formal interaction studies have not been conducted with other chemotherapy agents.

Warfarin:
A single 125-mg dose of oral aprepitant was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic warfarin therapy. Although there was no effect of oral aprepitant on the plasma AUC of R(+)- or S(-)-warfarin determined on Day 3, there was a 34% decrease in S(-)-warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with oral aprepitant.

In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of fosaprepitant with each chemotherapy cycle.

Tolbutamide:
Oral aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was administered orally prior to the administration of the 3-day regimen of oral aprepitant and on Days 4, 8, and 15.
Oral contraceptives:
Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinylestradiol and 1 mg of norethindrone, decreased the AUC of ethinylestradiol by 43%, and decreased the AUC of norethindrone by 8%.

In another study, a single dose of an oral contraceptive containing ethinylestradiol and norethindrone was administered on Days 1 through 21 with oral aprepitant, given as a regimen of 125 mg on Day 8 and 80 mg/day on Days 9 and 10 with ondansetron 32 mg IV on Day 8 and oral dexamethasone given as 12 mg on Day 8 and 8 mg/day on Days 9, 10, and 11. In the study, the AUC of ethinylestradiol decreased by 19% on Day 10 and there was as much as a 64% decrease in ethinylestradiol trough concentrations during Days 9 through 21. While there was no effect of oral aprepitant on the AUC of norethindrone on Day 10, there was as much as a 60% decrease in norethindrone trough concentrations during Days 9 through 21.

The efficacy of hormonal contraceptives during and for 28 days after administration of fosaprepitant may be reduced. Alternative or back-up methods of contraception should be used during treatment with fosaprepitant and for 1 month following administration of fosaprepitant.

Midazolam:
Fosaprepitant 150 mg administered as a single intravenous dose on Day 1 increased the AUC0–∞ of midazolam by approximately 1.8-fold on Day 1 and had no effect (1.0-fold) on Day 4 when midazolam was coadministered as a single oral dose of 2 mg on Days 1 and 4. Fosaprepitant 150 mg IV is a weak CYP3A4 inhibitor as a single dose on Day 1 with no evidence of inhibition or induction of CYP3A4 observed on Day 4.

Effect of other agents on the pharmacokinetics of aprepitant
Aprepitant is a substrate for CYP3A4; therefore, coadministration of fosaprepitant with drugs that inhibit CYP3A4 activity may result in increased plasma concentrations of aprepitant. Consequently, concomitant administration of fosaprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole) should be approached cautiously; but concomitant administration of aprepitant with moderate CYP3A4 inhibitors (e.g., diltiazem) does not result in clinically meaningful changes in plasma concentrations of aprepitant.

Aprepitant is a substrate for CYP3A4; therefore, coadministration of fosaprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin) may result in reduced plasma concentrations and decreased efficacy. Concomitant administration of fosaprepitant with St. John's Wort is not recommended.

Ketoconazole:
When a single 125-mg dose of oral aprepitant was administered on Day 5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold. Concomitant administration of fosaprepitant with strong CYP3A4 inhibitors should be approached cautiously.

Rifampicin:
When a single 375-mg dose of oral aprepitant was administered on Day 9 of a 14-day regimen of 600 mg/day of rifampicin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold. Coadministration of fosaprepitant with drugs that induce CYP3A4 activity may result in reduced plasma concentrations and decreased efficacy.
Additional interactions

**Diltiazem:**
In patients with mild to moderate hypertension, infusion of 100 mg fosaprepitant over 15 minutes with diltiazem 120 mg 3 times daily, resulted in a 1.5-fold increase of aprepitant AUC and a 1.4-fold increase in diltiazem AUC. The pharmacokinetic effects resulted in a small but clinically meaningful decrease in diastolic blood pressure (decrease of 16.8 mm Hg with fosaprepitant versus 10.5 mm Hg without fosaprepitant) and may result in a small but clinically meaningful decrease in systolic blood pressure (decrease of 24.4 mm Hg with fosaprepitant versus 18.8 mm Hg without fosaprepitant), but did not result in a clinically meaningful change in heart rate, or PR interval, beyond those changes induced by diltiazem alone.

**Paroxetine:**
Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and $C_{\text{max}}$ by approximately 20% of both aprepitant and paroxetine.

4.6 FERTILITY, PREGNANCY AND LACTATION

**Effects on fertility**
Fosaprepitant, when administered intravenously, is rapidly converted to aprepitant, particularly in rats. The effect of fosaprepitant on fertility has not been established at exposures expected with clinical use of the drug. In the fertility studies conducted with fosaprepitant and aprepitant, the highest systemic exposures to aprepitant were obtained following oral administration of aprepitant.

Aprepitant administered to male or female rats at oral doses up to 1,000 mg/kg twice daily (approximately 1.5 times the adult human dose based on systemic exposure following oral aprepitant 125 mg in females, or lower than the adult human dose in males) had no effects on mating performance, fertility, or embryonic/foetal survival. Sperm count and motility were unaffected in males.

**Use in pregnancy (Category B2)**
Fosaprepitant, when administered intravenously, is rapidly converted to aprepitant, particularly in the species used in the reproductive toxicity studies and the potential teratogenicity of fosaprepitant at exposures equivalent to those expected with clinical use has not been established. In the teratology studies conducted with fosaprepitant and aprepitant, the highest systemic exposures to aprepitant were obtained following oral administration of aprepitant.

Reproductive studies with oral aprepitant have been performed in rats and rabbits at doses up to 1.5 times the systemic exposure at the adult human dose following oral aprepitant 125 mg and have revealed no evidence of harm to the foetus. Given that there are no adequate and well-controlled studies in pregnant women and that the potential teratogenicity of fosaprepitant at exposures equivalent to those expected with clinical use has not been established, this drug should not be used during pregnancy unless the clinical benefit to the mother outweighs any potential harm to the foetus.

**Use in lactation**
EMEND IV, when administered intravenously, is rapidly converted to aprepitant.

Significant concentrations of aprepitant were observed in the milk of lactating rats. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the possible adverse effects of aprepitant on nursing infants, a
decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

The effects of this medicine on a person’s ability to drive and use machines were not assessed as part of its registration. However, certain side effects that have been reported with EMEND IV may affect some patients’ ability to drive or operate machinery. Individual responses to EMEND IV may vary.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

The overall safety of fosaprepitant was evaluated in approximately 1600 individuals.

**Moderately Emetogenic Chemotherapy (MEC)**

In an active-controlled clinical trial in patients receiving MEC, safety was evaluated in 504 patients receiving a single dose of EMEND IV in combination with ondansetron and dexamethasone (fosaprepitant regimen) compared to 497 patients receiving ondansetron and dexamethasone alone (control regimen). The following clinically important drug-related adverse experiences were reported in patients treated with the fosaprepitant regimen and at a greater incidence than in the control group.

[Common (≥1/100, <1/10), Uncommon (≥1/1000, <1/100)]

**Cardiac disorders:**

Uncommon: palpitations

**Gastrointestinal disorders:**

Common: constipation
Uncommon: abdominal distension, abdominal pain, abdominal pain upper, dyspepsia

**General disorders and administration site conditions:**

Common: infusion site pain
Uncommon: asthenia

**Infections and infestations:**

Uncommon: oral candidiasis

**Metabolism and nutrition disorders:**

Uncommon: decreased appetite

**Respiratory, thoracic and mediastinal disorders:**

Uncommon: cough, oropharyngeal pain, throat irritation

**Vascular disorders:**

Uncommon: hot flush

**Highly Emetogenic Chemotherapy (HEC)**

In an active-controlled clinical study in patients receiving highly emetogenic chemotherapy, safety was evaluated for 1143 patients receiving a single dose of EMEND IV 150 mg compared to 1169 patients receiving the 3-day regimen of aprepitant. The safety profile was generally similar to that seen in the MEC study with fosaprepitant.

The following additional clinically important drug-related adverse experiences occurred with fosaprepitant 150 mg and have not been reported in earlier clinical studies with oral aprepitant, or in the MEC study with fosaprepitant.
[Uncommon (≥1/1000, <1/100), Rare (≥1/10,000, <1/1,000)]

**General disorders and administration site conditions:**
Uncommon: infusion site erythema, infusion site pruritus.
Rare: infusion site induration.

**Investigations:**
Uncommon: blood pressure increased.

**Skin and subcutaneous tissue disorders:**
Uncommon: erythema.

**Vascular disorders:**
Uncommon: flushing, thrombophlebitis (predominantly, infusion-site thrombophlebitis).

**Aprepitant Adverse Effects**
Since fosaprepitant is converted to aprepitant, those adverse experiences associated with aprepitant might also be expected to occur with EMEND IV.

The overall safety of aprepitant was evaluated in approximately 6500 individuals.

**PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV)**

In 2 well-controlled clinical trials in patients receiving highly emetogenic cancer chemotherapy (HEC), 544 patients were treated with the 3-day oral aprepitant regimen during Cycle 1 of chemotherapy and 413 of these patients continued into the Multiple-Cycle extension for up to 6 cycles of chemotherapy. In 2 well-controlled clinical trials in patients receiving moderately emetogenic cancer chemotherapy, 868 patients were treated with the 3-day oral aprepitant regimen during Cycle 1 of chemotherapy and 686 of these patients continued into the Multiple-Cycle extensions for up to 4 cycles of chemotherapy. The 3-day oral Aprepitant regimen was given in combination with ondansetron and dexamethasone and was generally well tolerated. Most adverse experiences reported in these clinical studies were described as mild to moderate in intensity.

**Highly Emetogenic Chemotherapy (HEC)**

In Cycle 1, in patients receiving HEC, drug-related clinical adverse experiences were reported in approximately 19% of patients treated with the 3-day oral aprepitant regimen, compared with approximately 14% of patients treated with standard therapy. Treatment was discontinued due to drug-related clinical adverse experiences in 0.6% of patients treated with the 3-day oral aprepitant regimen, compared with 0.4% of patients treated with standard therapy. Table 3 shows the drug-related adverse experiences reported at an incidence ≥0.5% (and at a greater incidence than standard therapy) in patients treated with the 3-day oral aprepitant regimen.
Table 3
Drug-Related Adverse Experiences (Incidence ≥ 0.5% and Greater Than Standard Therapy) Occurring in Patients Receiving HEC Who Were Treated With the 3-Day Oral Aprepitant Regimen for CINV in Clinical Studies

<table>
<thead>
<tr>
<th>Category</th>
<th>Aprepitant Regimen* (N = 544)</th>
<th>Standard Therapy** (N = 550)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood and Lymphatic System Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaemia</td>
<td>0.6</td>
<td>0.0</td>
</tr>
<tr>
<td><strong>Metabolism and Nutrition Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>2.0</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>Nervous System Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>0.9</td>
<td>0.7</td>
</tr>
<tr>
<td>Headache</td>
<td>2.0</td>
<td>1.8</td>
</tr>
<tr>
<td><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hiccups</td>
<td>4.6</td>
<td>2.9</td>
</tr>
<tr>
<td><strong>Gastrointestinal Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>0.9</td>
<td>0.5</td>
</tr>
<tr>
<td>Constipation</td>
<td>2.4</td>
<td>2.0</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>1.1</td>
<td>0.9</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>2.6</td>
<td>2.0</td>
</tr>
<tr>
<td>Gastroesophageal reflux disease</td>
<td>0.7</td>
<td>0.2</td>
</tr>
<tr>
<td>Nausea†</td>
<td>0.7</td>
<td>0.0</td>
</tr>
<tr>
<td><strong>General Disorders and Administrative Site Conditions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenia</td>
<td>1.5</td>
<td>0.2</td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT increased</td>
<td>2.8</td>
<td>1.1</td>
</tr>
<tr>
<td>AST increased</td>
<td>1.1</td>
<td>0.7</td>
</tr>
<tr>
<td>Blood alkaline phosphatase increased</td>
<td>0.7</td>
<td>0.2</td>
</tr>
</tbody>
</table>

*Aprepitant Regimen: Aprepitant 125 mg orally on Day 1 and 80 mg orally once daily on Days 2 and 3 plus Ondansetron 32 mg IV on Day 1 and dexamethasone 12 mg orally on Day 1 and 8 mg orally once daily on Days 2 to 4.**

**Standard Therapy: Placebo plus Ondansetron 32 mg IV on Day 1 and dexamethasone 20 mg orally on Day 1 and 8 mg orally twice daily on Days 2 to 4.

†These adverse experiences of nausea occurred 2 or 3 days after the last dose of study drug (Study Day 6 or greater; i.e., after the period in which efficacy was assessed).

In an additional active-controlled clinical study in 1169 patients receiving the 3-day oral aprepitant regimen and HEC, the adverse experience profile was generally similar to that seen in the other HEC studies with the 3-day oral aprepitant regimen.

Moderately Emetogenic Chemotherapy (MEC)

In the combined analysis of Cycle 1 data in patients receiving MEC, drug-related adverse experiences were reported in approximately 14% of patients treated with the 3-day oral aprepitant regimen compared with approximately 15% of patients treated with standard therapy. Treatment was discontinued due to drug-related adverse experiences in 0.7% of patients treated with the 3-day oral aprepitant regimen compared with 0.2% of patients treated with standard therapy. Table 4 shows the drug-related adverse experiences reported at an incidence ≥0.5% and at a greater incidence than standard therapy in patients treated with the 3-day oral aprepitant regimen.
**Table 4**

<table>
<thead>
<tr>
<th>Drug-Related Adverse Experiences (Incidence ≥0.5% and Greater Than Standard Therapy) Occurring in Patients Receiving MEC Who Were Treated With the 3-day Oral Aprepitant Regimen for CINV in Clinical Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Aprepitant Regimen</strong></td>
</tr>
<tr>
<td>(N = 868)</td>
</tr>
<tr>
<td><strong>Standard Therapy</strong></td>
</tr>
<tr>
<td>(N = 846)</td>
</tr>
<tr>
<td><strong>Psychiatric Disorders</strong></td>
</tr>
<tr>
<td>Anxiety</td>
</tr>
<tr>
<td>0.5</td>
</tr>
<tr>
<td>0.0</td>
</tr>
<tr>
<td><strong>Nervous System Disorders</strong></td>
</tr>
<tr>
<td>Dizziness</td>
</tr>
<tr>
<td>0.7</td>
</tr>
<tr>
<td>0.6</td>
</tr>
<tr>
<td>Somnolence</td>
</tr>
<tr>
<td>0.6</td>
</tr>
<tr>
<td>0.2</td>
</tr>
<tr>
<td><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></td>
</tr>
<tr>
<td>Hiccups</td>
</tr>
<tr>
<td>0.5</td>
</tr>
<tr>
<td>0.2</td>
</tr>
<tr>
<td><strong>Gastrointestinal Disorders</strong></td>
</tr>
<tr>
<td>Dyspepsia</td>
</tr>
<tr>
<td>0.8</td>
</tr>
<tr>
<td>0.4</td>
</tr>
<tr>
<td>Eructation</td>
</tr>
<tr>
<td>1.0</td>
</tr>
<tr>
<td>0.1</td>
</tr>
<tr>
<td><strong>General Disorders and Administration Site Conditions</strong></td>
</tr>
<tr>
<td>Fatigue</td>
</tr>
<tr>
<td>1.4</td>
</tr>
<tr>
<td>0.9</td>
</tr>
</tbody>
</table>

* Aprepitant Regimen: Aprepitant 125 mg orally on Day 1 and 80 mg orally on Days 2 and 3 plus ondansetron 8 mg orally twice on Day 1 plus dexamethasone 12 mg orally on Day 1.
** Standard Therapy: Placebo plus ondansetron 8 mg orally (twice on Day 1 and every 12 hours on Days 2 and 3) plus dexamethasone 20 mg orally on Day 1.

**Highly and Moderately Emetogenic Chemotherapy**

In a pooled analysis of the HEC and MEC studies, the following drug-related adverse experiences were reported in patients treated with the 3-day oral aprepitant regimen at a greater incidence than standard therapy and not described above:

Blood and lymphatic system disorders: febrile neutropenia

Infection and infestations: candidiasis, staphylococcal infection.

Metabolism and nutrition disorders: polydipsia.

Psychiatric disorders: disorientation, euphoric mood.

Nervous system disorders: cognitive disorder, lethargy, dysgeusia.

Eye disorders: conjunctivitis.

Ear and labyrinth disorders: tinnitus.

Cardiac disorders: cardiovascular disorder, bradycardia, palpitations.

Vascular disorders: hot flush.

Respiratory, thoracic and mediastinal disorders: cough, oropharyngeal pain, postnasal drip, sneezing, throat irritation.

Gastrointestinal disorders: abdominal distension, dry mouth, faeces hard, flatulence, neutropenic colitis, duodenal ulcer perforation, stomatitis, vomiting.

Skin and subcutaneous tissue disorders: acne, hyperhidrosis, seborrhoea, photosensitivity reaction, rash pruritic, rash, skin lesion.

Musculoskeletal and connective tissue disorders: muscular weakness, muscle spasms.

Renal and urinary disorders: dysuria, pollakiuria.

General disorders and administration site conditions: chest discomfort, oedema, gait disturbance, malaise.

Investigations: blood sodium decreased, red blood cells urine positive, neutrophil count decreased, weight decreased, glucose urine present, urine output increased.

The adverse experience profiles in the Multiple-Cycle extensions of HEC and MEC studies for up to 6 cycles of chemotherapy were generally similar to those observed in Cycle 1.
In other clinical studies, isolated cases of serious adverse experiences were reported. In another chemotherapy induced nausea and vomiting (CINV) study, Stevens-Johnson syndrome was reported as a serious adverse experience in a patient receiving aprepitant with cancer chemotherapy. Angioedema and urticaria were reported in a patient receiving aprepitant in a non-CINV study.

Oral administration of a single 165-mg dose of aprepitant was generally well tolerated in healthy adults.

Based on a comparable pharmacokinetic/pharmacodynamic profile, the 1-day oral regimen of aprepitant 165 mg administered in the fasted state or with a light (low fat) meal is anticipated to have a similar safety and tolerability profile to that of the 1-day regimen of fosaprepitant 150 mg and the 3-day oral aprepitant regimen in chemotherapy patients (see PHARMACOLOGY).

**Laboratory Adverse Experiences**

One laboratory adverse experience, haemoglobin decreased (40 mg aprepitant 3.8%, ondansetron 4.2%), was reported at an incidence ≥3% in a patient receiving general anaesthesia.

The following additional laboratory adverse experiences (incidence >0.5% and greater than ondansetron), regardless of causality, were reported in patients treated with aprepitant 40 mg: blood albumin decreased, blood bilirubin increased, blood glucose increased, blood potassium decreased, glucose urine present.

The adverse experience of ALT increased occurred with similar incidence in patients treated with aprepitant 40 mg (1.1%) as in patients treated with ondansetron 4 mg (1.0%).

**Other Studies**

Angioedema and urticaria were reported as serious adverse experiences in a patient receiving aprepitant in a non-CINV/non-PONV study.

**Post-Marketing Experience**

The following adverse reactions have been identified during post-marketing use. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to the drug.

**Skin and subcutaneous tissue disorders:**
Pruritus, rash, urticaria, rarely Stevens-Johnson syndrome/toxic epidermal necrolysis.

**Immune system disorders:**
Hypersensitivity reactions including anaphylactic reactions/anaphylactic shock.

Immediate hypersensitivity or anaphylactic reactions have been observed during the infusion of fosaprepitant which may include the following: flushing, erythema, rash, chest tightness, wheezing, dyspnoea (see Section 4.4 Special Warnings and Precaution for Use).

**Reporting suspected adverse effects**

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at http://www.tga.gov.au/reporting-problems.
4.9 OVERDOSE

No specific information is available on the treatment of overdosage. Single doses up to 200 mg of fosaprepitant IV and 600 mg of aprepitant were generally well tolerated in healthy subjects. Three out of 33 subjects receiving 200 mg of fosaprepitant experienced mild injection site thrombosis. Aprepitant was generally well tolerated when administered as 375 mg once daily for up to 42 days to patients in non-CINV studies. In 33 cancer patients, administration of a single 375-mg dose of aprepitant on Day 1 and 250 mg once daily on Days 2 to 5 was generally well tolerated.

Drowsiness and headache were reported in one patient who ingested 1440 mg of aprepitant.

In the event of overdose, EMEND IV should be discontinued and general supportive treatment and monitoring should be provided. Because of the antiemetic activity of aprepitant, drug-induced emesis may not be effective.

Aprepitant cannot be removed by haemodialysis.

For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of action

Fosaprepitant is a prodrug of aprepitant and accordingly, its antiemetic effects are attributable to aprepitant.

Aprepitant has a unique mode of action; it is a selective high affinity antagonist at human substance P neurokinin 1 (NK₁) receptors. Counter-screening assays showed that aprepitant was at least 3,000-fold selective for the NK₁ receptor over other enzyme, transporter, ion channel and receptor sites including the dopamine and serotonin receptors that are the targets of existing therapy for chemotherapy-induced nausea and vomiting (CINV).

NK₁-receptor antagonists have been shown pre-clinically to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Preclinical and human Positron Emission Tomography (PET) studies with aprepitant have shown that it is brain penetrant and occupies brain NK₁ receptors. Preclinical studies show that aprepitant has a long duration of central activity, inhibits both the acute and delayed phases of cisplatin-induced emesis, and augments the antiemetic activity of the 5-HT₃-receptor antagonist ondansetron and the corticosteroid dexamethasone against cisplatin-induced emesis.

Cardiac electrophysiology

In a randomised, double-blind, positive controlled, thorough QTc study, a single 200 mg dose of fosaprepitant had no effect on the QTc interval.

Brain NK₁ receptor occupancy assessed by positron emission tomography

A positron emission tomography study in healthy young men administered a single intravenous dose of 150 mg fosaprepitant (N=8) demonstrated brain NK₁ receptor occupancy of ≥100% at T_max, and 24 hours, ≥97% at 48 hours, and between 41% and 75% at 120 hours, following dosing. Occupancy of brain NK₁ receptors, in this study, correlate well with aprepitant plasma concentrations.
Clinical trials
Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)

**Highly Emetogenic Chemotherapy (HEC)**
In a randomised, parallel, double-blind, active-controlled study, fosaprepitant 150 mg (N=1147) as a single intravenous infusion was compared with a 3-day aprepitant regimen (N=1175) in patients receiving a highly emetogenic chemotherapy regimen that included cisplatin (≥70 mg/m²). Other concomitant chemotherapy agents commonly administered were fluorouracil, gemcitabine, paclitaxel, and etoposide. All patients in both groups received dexamethasone and ondansetron (see Table 5).

<table>
<thead>
<tr>
<th>Table 5: Treatment Regimens in HEC Trial*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td><strong>CINV Fosaprepitant Regimen</strong></td>
</tr>
<tr>
<td>Fosaprepitant</td>
</tr>
<tr>
<td>150 mg intravenously over 20 to 30 minutes</td>
</tr>
<tr>
<td>approximately 30 minutes prior to</td>
</tr>
<tr>
<td>chemotherapy</td>
</tr>
<tr>
<td>none</td>
</tr>
<tr>
<td>none</td>
</tr>
<tr>
<td>none</td>
</tr>
<tr>
<td>Oral dexamethasone†</td>
</tr>
<tr>
<td>12 mg</td>
</tr>
<tr>
<td>8 mg</td>
</tr>
<tr>
<td>8 mg twice daily</td>
</tr>
<tr>
<td>8 mg twice daily</td>
</tr>
<tr>
<td>Ondansetron</td>
</tr>
<tr>
<td>Ondansetron‡</td>
</tr>
<tr>
<td>none</td>
</tr>
<tr>
<td>none</td>
</tr>
<tr>
<td>none</td>
</tr>
<tr>
<td><strong>CINV Oral Aprepitant Regimen</strong></td>
</tr>
<tr>
<td>Aprepitant capsules</td>
</tr>
<tr>
<td>125 mg</td>
</tr>
<tr>
<td>80 mg</td>
</tr>
<tr>
<td>80 mg</td>
</tr>
<tr>
<td>none</td>
</tr>
<tr>
<td>Oral dexamethasone§</td>
</tr>
<tr>
<td>12 mg</td>
</tr>
<tr>
<td>8 mg</td>
</tr>
<tr>
<td>8 mg</td>
</tr>
<tr>
<td>8 mg</td>
</tr>
<tr>
<td>Ondansetron</td>
</tr>
<tr>
<td>Ondansetron‡</td>
</tr>
<tr>
<td>none</td>
</tr>
<tr>
<td>none</td>
</tr>
<tr>
<td>none</td>
</tr>
</tbody>
</table>

* Fosaprepitant placebo, aprepitant capsules placebo and dexamethasone placebo (in the evenings on Days 3 and 4) were used to maintain blinding.
† Dexamethasone was administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 through 4. Dexamethasone was also administered in the evenings on Days 3 and 4. The 12 mg dose of dexamethasone on Day 1 and the 8 mg once daily dose on Day 2 reflects a dosage adjustment to account for a drug interaction with the fosaprepitant regimen (see Section 5 Pharmacological Properties, Mechanism of action).
‡ Ondansetron 32 mg intravenous was used in the clinical trials of fosaprepitant and aprepitant. Although this dose was used in clinical trials, this is no longer the currently recommended dose. Refer to the package insert for the selected 5-HT₃ antagonist for the current recommended dose.
§ Dexamethasone was administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 through 4. The 12 mg dose of dexamethasone on Day 1 and the 8 mg once daily dose on Days 2 through 4 reflects a dosage adjustment to account for a drug interaction with the oral aprepitant regimen (see Section 5 Pharmacological Properties, Mechanism of action).

Efficacy was based on the evaluation of the following composite measures: complete response in both the overall and delayed phases and no vomiting in the overall phase. EMEND IV 150 mg was shown to be non-inferior to that of the 3-day regimen of aprepitant. A summary of the primary and secondary endpoints is shown in Table 6.
Table 6: Percent of Patients Receiving Highly Emetogenic Chemotherapy Responding by Treatment Group and Phase - Cycle 1

<table>
<thead>
<tr>
<th>ENDPOINTS*</th>
<th>Fosaprepitant Regimen (N =1106) **</th>
<th>Aprepitant Regimen (N =1134) **</th>
<th>Difference† (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete Response‡</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall§</td>
<td>71.9 %</td>
<td>72.3 %</td>
<td>-0.4 (-4.1, 3.3)</td>
</tr>
<tr>
<td>Delayed phase §§</td>
<td>74.3 %</td>
<td>74.2 %</td>
<td>0.1 (-3.5, 3.7)</td>
</tr>
<tr>
<td>No Vomiting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall§</td>
<td>72.9 %</td>
<td>74.6 %</td>
<td>-1.7 (-5.3, 2.0)</td>
</tr>
</tbody>
</table>

* Primary endpoint is bolded.
** N: Number of patients included in the primary analysis of complete response.
† Difference and confidence interval (CI) were calculated using the method proposed by Miettinen and Nurminen and adjusted for Gender.
‡ Complete Response = no vomiting and no use of rescue therapy.
§ Overall = 0 to 120 hours post-initiation of cisplatin chemotherapy.
§§ Delayed phase = 25 to 120 hours post-initiation of cisplatin chemotherapy.

Moderately Emetogenic Chemotherapy (MEC)
In a randomized, parallel, double-blind, active comparator-controlled study, fosaprepitant 150 mg as a single intravenous infusion (N=502) in combination with ondansetron and dexamethasone (fosaprepitant regimen) was compared with ondansetron and dexamethasone alone (control regimen) (N=498) (see Table 7) in patients receiving a moderately emetogenic chemotherapy regimen. The most commonly administered MEC chemotherapeutic agents were carboplatin, oxaliplatin, and cyclophosphamide.

Table 7: Treatment Regimens in MEC Trial*

<table>
<thead>
<tr>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CINV Fosaprepitant Regimen</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fosaprepitant</td>
<td>150 mg intravenously over 20 to 30 minutes approximately 30 minutes prior to chemotherapy</td>
<td>none</td>
</tr>
<tr>
<td>Oral Dexamethasone †</td>
<td>12 mg</td>
<td>none</td>
</tr>
<tr>
<td>Oral Ondansetron †</td>
<td>8 mg for 2 doses</td>
<td>none</td>
</tr>
<tr>
<td><strong>CINV Control Regimen</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Dexamethasone</td>
<td>20 mg</td>
<td>none</td>
</tr>
<tr>
<td>Oral Ondansetron †</td>
<td>8 mg for 2 doses</td>
<td>8 mg twice daily</td>
</tr>
</tbody>
</table>

* Fosaprepitant placebo and dexamethasone placebo (on Day 1) were used to maintain blinding.
† Dexamethasone was administered 30 minutes prior to chemotherapy treatment on Day 1. The 12 mg dose reflects a dosage adjustment to account for a drug interaction with the fosaprepitant regimen (see **Section 5 Pharmacological Properties, Mechanism of action**).
‡ The first ondansetron dose was administered 30 to 60 minutes prior to chemotherapy treatment on Day 1 and the second dose was administered 8 hours after first ondansetron dose.

The efficacy of fosaprepitant was evaluated based on the primary and secondary endpoints listed in Table 8 and was shown to be superior to the control regimen with regard to complete response in the delayed and overall phases.
Table 8: Percent of Patients Receiving Moderately Emetogenic Chemotherapy Responding by Treatment Group and Phase

<table>
<thead>
<tr>
<th>ENDPOINTS</th>
<th>Fosaprepitant Regimen (N = 502)* %</th>
<th>Control Regimen (N = 498)* %</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRIMARY ENDPOINT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete Response†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delayed phase‡</td>
<td>78.9</td>
<td>68.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>KEY SECONDARY ENDPOINTS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete Response†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall§</td>
<td>77.1</td>
<td>66.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Acute phase¶</td>
<td>93.2</td>
<td>91</td>
<td>0.184</td>
</tr>
</tbody>
</table>

* N: Number of patients included in the intention to treat population.
† Complete Response = no vomiting and no use of rescue therapy.
‡ Delayed phase = 25 to 120 hours post-initiation of chemotherapy.
§ Overall = 0 to 120 hours post-initiation of chemotherapy.
¶ Acute phase = 0 to 24 hours post-initiation of chemotherapy.

The Kaplan-Meier curves in Figure 1 show that the time to first vomiting was longer in subjects in the fosaprepitant regimen compared with the control regimen (nominal p-value <0.001 by log-rank test).

Figure 1: Percent of Patients Receiving Moderately Emetogenic Chemotherapy Who Remain Emesis Free Over Time

Fosaprepitant Regimen: fosaprepitant 150 mg on Day 1 in combination with ondansetron 16 mg orally on Day 1 and dexamethasone 12 mg on Day 1. Days 2-3: placebo for ondansetron every 12 hours.
Control Regimen: 16 mg ondansetron orally on Day 1 in combination with 20 mg dexamethasone orally on Day 1. Days 2-3: 8 mg ondansetron orally twice daily.
5.2 PHARMACOKINETIC PROPERTIES

Absorption
EMEND IV is dosed intravenously and therefore is immediately and completely bioavailable.

Aprepitant after Fosaprepitant Administration
Following a single intravenous 150-mg dose of fosaprepitant administered as a 20-minute infusion to healthy volunteers the mean AUC\textsubscript{0-\textinfty} of aprepitant was 35.0 mcg.hr/mL and the mean maximal aprepitant concentration was 4.01 mcg/mL.

Distribution
Fosaprepitant is rapidly converted to aprepitant.

Aprepitant is greater than 95% bound to plasma proteins. The geometric mean apparent volume of distribution at steady state (V\textsubscript{dss}) is approximately 66 L in humans.

Aprepitant crosses the placenta in rats, and crosses the blood brain barrier in rats and ferrets. PET studies in humans indicate that aprepitant crosses the blood brain barrier (see Section 5.1 Pharmacodynamic Properties, Mechanism of action).

Metabolism
Fosaprepitant was rapidly converted to aprepitant in \textit{in vitro} incubations with liver preparations from nonclinical species (rat and dog) and humans. Furthermore, fosaprepitant underwent rapid and nearly complete conversion to aprepitant in S9 preparations from multiple other human tissues including kidney, lung and ileum. Thus, it appears that the conversion of fosaprepitant to aprepitant can occur in multiple extrahepatic tissues in addition to the liver. In humans, fosaprepitant administered intravenously was rapidly converted to aprepitant within 30 minutes following the end of infusion.

Aprepitant undergoes extensive metabolism. In healthy young adults, aprepitant accounts for approximately 24% of the radioactivity in plasma over 72 hours following a single oral 300 mg dose of \[^{14}\text{C} \text{-aprepitant, indicating a substantial presence of metabolites in the plasma. Seven metabolites of aprepitant, which are only weakly active, have been identified in human plasma. The metabolism of aprepitant occurs largely via oxidation at the morpholine ring and its side chains. \textit{In vitro} studies using human liver microsomes indicate that aprepitant is metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E1.}

All metabolites observed in urine, faeces and plasma following an intravenous 100 mg \[^{14}\text{C} \text{-fosaprepitant dose were also observed following an oral dose of \[^{14}\text{C} \text{-aprepitant. Upon conversion of 245.3 mg of fosaprepitant dimeglumine (equivalent to 150 mg fosaprepitant free acid) to aprepitant, 23.9 mg of phosphoric acid and 95.3 mg of meglumine are liberated.}

Excretion
Following administration of a single IV 100 mg dose of \[^{14}\text{C} \text{-fosaprepitant to healthy subjects, 57% of the radioactivity was recovered in urine and 45% in faeces.}

Aprepitant is eliminated primarily by metabolism. No aprepitant is excreted unchanged in the urine. Following administration of a single oral 300-mg dose of \[^{14}\text{C} \text{-aprepitant to healthy subjects, 5% of the radioactivity was recovered in urine and 86% in faeces.}

The mean apparent terminal half-life of aprepitant following fosaprepitant administration was approximately 14 hours.
Special populations

**Gender**
Following oral administration of a single dose of aprepitant, the AUC\textsubscript{0-24hr} and C\textsubscript{max} for aprepitant are 9% and 17% higher, respectively in females as compared with males. The half-life of aprepitant is approximately 25% lower in females as compared with males and its T\textsubscript{max} occurs at approximately the same time. These differences are not considered clinically meaningful. No dosage adjustment is necessary based on gender.

**Elderly**
Following oral administration of a single 125-mg dose of aprepitant on Day 1 and 80 mg once daily on Days 2 through 5, the AUC\textsubscript{0-24hr} of aprepitant was 21% higher on Day 1 and 36% higher on Day 5 in elderly (≥65 years) relative to younger adults. The C\textsubscript{max} was 10% higher on Day 1 and 24% higher on Day 5 in elderly relative to younger adults. These differences are not considered clinically meaningful. No dosage adjustment is necessary in elderly patients.

**Race**
Following oral administration of a single dose of aprepitant, the AUC\textsubscript{0-24hr} is approximately 27% and 31% higher in Hispanics as compared with Caucasians and Blacks, respectively. The C\textsubscript{max} is 19% and 29% higher in Hispanics as compared with Caucasians and Blacks, respectively. Single dose administration of oral aprepitant in Asians resulted in a 74% and 47% increase in AUC\textsubscript{0-24hr} and C\textsubscript{max}, respectively, as compared to Caucasians. These differences are not considered clinically meaningful. No dosage adjustment is necessary based on race.

**Body Mass Index (BMI)**
Body Mass Index (BMI) had no clinically meaningful effect on the pharmacokinetics of aprepitant.

**Renal insufficiency**
A single 240-mg dose of oral aprepitant was administered to patients with severe renal insufficiency (CrCl<30 mL/min) and to patients with end stage renal disease (ESRD) requiring haemodialysis.

In patients with severe renal insufficiency, the AUC\textsubscript{0-∞} of total aprepitant (unbound and protein bound) decreased by 21% and C\textsubscript{max} decreased by 32%, relative to healthy subjects. In patients with ESRD undergoing haemodialysis, the AUC\textsubscript{0-∞} of total aprepitant decreased by 42% and C\textsubscript{max} decreased by 32%. Due to modest decreases in protein binding of aprepitant in patients with renal disease, the AUC of pharmacologically active unbound drug was not significantly affected in patients with renal insufficiency compared with healthy subjects. Haemodialysis conducted 4 or 48 hours after dosing had no significant effect on the pharmacokinetics of aprepitant; less than 0.2% of the dose was recovered in the dialysate.

No dosage adjustment for EMEND IV is necessary for patients with severe renal insufficiency or for patients with ESRD undergoing haemodialysis, based on the pharmacokinetics of aprepitant in these patients, although no clinical studies have been conducted to determine whether efficacy is affected.

**Hepatic insufficiency**
Fosaprepitant is metabolized in various extrahepatic tissues; therefore hepatic insufficiency is not expected to alter the conversion of fosaprepitant to aprepitant.

Oral aprepitant was well tolerated in patients with mild to moderate hepatic insufficiency. Following administration of a single 125-mg dose of oral aprepitant on Day 1 and 80 mg once daily on Days 2 and 3 to patients with mild hepatic insufficiency (Child-Pugh score 5 to 6), the AUC\textsubscript{0-24hr} of aprepitant was 11% lower on Day 1 and 36% lower on Day 3, as compared with healthy subjects given the same regimen. In patients with moderate hepatic insufficiency (Child-Pugh score 7 to 9), the AUC\textsubscript{0-24hr} of aprepitant was 10% higher on Day 1 and 18% higher
on Day 3, as compared with healthy subjects given the same regimen. These differences in AUC0-24hr are not considered clinically meaningful; therefore, no dosage adjustment is necessary in patients with mild to moderate hepatic insufficiency.

There are no clinical or pharmacokinetic data in patients with severe hepatic insufficiency (Child-Pugh score >9).

**Paediatric patients**
Fosaprepitant has not been evaluated in patients below 18 years of age.

### 5.3 PRECLINICAL SAFETY DATA

**Genotoxicity**
Fosaprepitant and aprepitant were both negative in the following genotoxicity assays: *in vitro* microbial and TK6 human lymphoblastoid cell mutagenesis assays, the *in vitro* alkaline elution/rat hepatocyte DNA strand break test, the *in vitro* chromosomal aberration assay in Chinese hamster ovary cells, and the *in vivo* mouse micronucleus assay in bone marrow.

**Carcinogenicity**
Carcinogenicity studies were not conducted with fosaprepitant but studies were conducted with aprepitant in mice and rats for approximately 2 years. In mice, aprepitant was not carcinogenic at doses up to 500 mg/kg/day (approximately 2 times the adult human dose based on systemic exposure). Rats developed hepatocellular adenomas at a dose of 25 mg/kg twice daily (females) and 125 mg/kg twice daily (males), thyroid follicular cell adenomas at a dose of 125 mg/kg twice daily (females and males), and thyroid follicular cell carcinomas at a dose of 125 mg/kg twice daily (males). Systemic exposures at these doses in rats were approximately equivalent to or lower than exposures in humans at the recommended dose. Tumours of these types are considered to be a consequence of hepatic CYP enzyme induction in the rat, and are consistent with changes observed in rats with other structurally and pharmacologically dissimilar compounds that have been shown to induce hepatic CYP enzymes. Consideration of the mechanisms involved in the development of these tumour types suggest that it is unlikely that there is any carcinogenic risk in humans at therapeutic dose levels of fosaprepitant or aprepitant.

### 6 PHARMACEUTICAL PARTICULARS

#### 6.1 LIST OF EXCIPIENTS

Each vial of EMEND IV 150 mg contains the following inactive ingredients: disodium edetate, polysorbate 80, lactose, sodium hydroxide and/or hydrochloric acid (for pH adjustment).

#### 6.2 INCOMPATIBILITIES

EMEND IV is incompatible with any solutions containing divalent cations (e.g., Ca^{2+}, Mg^{2+}), including Hartman’s and Lactated Ringer’s Solution. EMEND IV must not be reconstituted or mixed with solutions for which physical and chemical compatibility have not been established.

#### 6.3 SHELF LIFE

The expiry date can be found on the packaging. In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG).

#### 6.4 SPECIAL PRECAUTIONS FOR STORAGE
Store at 2 to 8°C (Refrigerate. Do not freeze).

6.5 NATURE AND CONTENTS OF CONTAINER

EMEND IV 150 mg is available as a single dose vial containing 150 mg of fosaprepitant free acid, in cartons containing 1 vial.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES

Fosaprepitant dimeglumine is a white to off-white amorphous powder. It is freely soluble in water.

Fosaprepitant dimeglumine is a prodrug of aprepitant and is chemically described as 1-Deoxy-1-(methylamino)-D-glucitol[3-[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl[methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]phosphonate (2:1) (salt).

Its empirical formula is C_{23}H_{22}F_{7}N_{4}O_{6}P, 2(C_{7}H_{17}NO_{5}) with a molecular weight of 1004.83.

Chemical structure

![Chemical structure of fosaprepitant dimeglumine](image)

CAS number
The CAS No. is 265121-04-8.

7 MEDICINE SCHEDULE (POISONS STANDARD)

Prescription Only Medicine (Schedule 4)

8 SPONSOR

Merck Sharp & Dohme (Australia) Pty Ltd
Level 1, Building A, 26 Talavera Road
Macquarie Park NSW 2113
www.msd-australia.com.au

9 DATE OF FIRST APPROVAL

20 August 2007

10 DATE OF REVISION

19 September 2022
SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.8</td>
<td>All references to Emend removed Relevant Adverse Effect information added verbatim from previously approved Emend PI</td>
</tr>
</tbody>
</table>

RCN: 000021850

Copyright © (2021) Merck & Co., Inc., Kenilworth, NJ, USA, and its affiliates. All rights reserved.